General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview


  • Kingella denitrificans is a Gram-negative, non-spore-forming, facultatively anaerobic, non-motile, short rod-shaped bacterium. It has been detected in at least 3 gut microbiome compilation studies or metastudies. The DNA G+C content is 54.1-54.8%. Kingella denitrificans is likely to be transient and not a long-term gut coloniser. (Snell1976)



  • This organism has been recovered from respiratory tract. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. Likely to be transient and not a long-term gut commensal.

  • GENERAL CHARACTERISTICS (Snell1976);
    Character Response
  • ±
  • Strain-dependent hydrolysis or digestion:
  • DNA;
  • 🧂
  • Salt tolerance:
  • doesn't tolerate 4% salt;
  • 💧
  • Bile tolerance:
  • Strain-variable at 10%
  • 🌡
  • Temperature tolerance:
  • doesn't grow at 5℃; grows at 30℃; grows at 37℃; doesn't grow at 45℃;
  • H+
  • Acid from carbohydrates usually produced:
  • glucose; maltose;
  • Active enzymes:
  • oxidase;
  • ±
  • Strain-dependent active enzymes:
  • DNase;

  • SPECIAL FEATURES (Snell1976);
    Character Response
  • Metabolites not produced:
  • H₂S; indole;
  • Haemolysis:
  • absent
  • Nitrate:
  • reduced
  • Nitrite:
  • reduced

  • RESPONSE TO ANTIBIOTICS (Snell1976);
    Class Active Resistant
  • Penicillins:
  • penicillin G;

  • Details


    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Betaproteobacteria Order:  Neisseriales Family:  Neisseriaceae Genus:  Kingella Gram stain:  neg O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Short Rod
    Health:  Unknown
    Source:  respiratory tract
    DNA G+C(%):  54.1-54.8
    Low T(℃):  5(neg)
    Lower T(℃):  30(+)
    Mid T(℃):  37(+)
    High T(℃):  45(neg)
    NaCl 3-5%:  4(neg)
    Bile reaction(%):  10(d)
    Urea:  neg Gelatin:  neg Starch:  neg Casein:  neg Arginine:  neg DNA:  d Tween:  20(d) 40(neg) 80(neg)

    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Galactose:  neg Glucose:  + Mannose:  neg Rhamnose:  neg Xylose:  neg Cellubiose:  neg Lactose:  neg Maltose:  + Sucrose:  neg Trehalose:  neg Adonitol:  neg Dulcitol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg Ethanol:  neg Salicin:  neg

    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Citrate:  neg 3-Hydroxybutyrate:  neg

    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  + Catalase:  neg Urease:  neg β-Galactosidase:  neg LysDC:  neg OrnDC:  neg DNAse:  d Lecithinase:  neg

    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    H2S:  neg Indole:  neg

    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    penicillin_G:  S(1U)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)

    References


    SPECIFIC REFERENCES FOR KINGELLA DENITRIFICANS
  • Snell1976 - Transfer of Some Saccharolytic Moraxella Species to Kingella Henriksen and Bøvre 1976, with Descriptions of Kingella indologenes sp. nov. and Kingella denitrificans sp. nov
  • ...............................
  • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR KINGELLA DENITRIFICANS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................